移动卒中单元成本效果的前瞻性多中心分析
本研究为前瞻性、多中心、交替周、整群对照试验,比较移动卒中单元(MSU)与急救医疗服务(EMS)在组织型纤溶酶原激活剂(tPA)给药中的成本效果。从CMS Medicare视角计算增量成本效果比(ICER),效果指标为基于EQ-5D-5L的质量调整生命年(QALY)。结果显示,全部tPA合格患者首年ICER为238,873美元/QALY,无既往残疾患者为61,199美元/QALY;终生ICER分别为94,710和31,259美元/QALY。限定卒中相关成本时ICER更低,且高度依赖MSU年治疗患者数。
要点
- 全部tPA合格患者首年ICER为238,873美元/QALY,无既往残疾患者为61,199美元/QALY。
- 终生ICER全部tPA合格患者为94,710美元/QALY,无既往残疾患者为31,259美元/QALY。
- 限定卒中相关成本时ICER更低,且高度依赖MSU年治疗患者数。
核心结论
- 考虑全部tPA合格患者首年总成本与结局时,MSU的成本效果处于临界水平。
- 基于无既往残疾患者、患者终生 horizon、卒中相关成本及MSU年治疗更多患者计算时,MSU具有成本效果至高度成本效果。
研究设计与样本
- 前瞻性、多中心、交替周、整群对照试验,比较MSU与EMS。
- 从CMS Medicare视角进行1年和终生成本效果分析,采用增量成本效果比(ICER)法。
- 效果指标为基于患者报告EQ-5D-5L数据估算的质量调整生命年(QALY)。
- 医疗利用通过全国平均Medicare报销额转换为成本。
- 另计算排除既往残疾患者及限定卒中相关成本的ICER。
主要发现
- 全部tPA合格患者首年ICER(基于MSU与EMS组总成本差异)为238,873美元/QALY;无既往残疾患者为61,199美元/QALY。
- 全部tPA合格患者终生ICER为94,710美元/QALY;无既往残疾患者为31,259美元/QALY。
- 限定卒中相关成本时,所有ICER均更低。
- ICER高度依赖MSU每年治疗的患者数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Given the high disease and cost burden of ischemic stroke, evaluating the clinical efficacy and cost-effectiveness of new approaches to prevent and treat ischemic stroke is critical. Effective ischemic stroke management depends on timely administration of thrombolytics after stroke onset. This study evaluates the cost-effectiveness associated with the use of mobile stroke units (MSUs) to expedite tissue plasminogen activator (tPA) administration, as compared with standard management through emergency medical services (EMS). METHODS: This study is a prospective, multicenter, alternating-week, cluster-controlled trial of MSU versus EMS. One-year and life-time cost-effectiveness analyses, using the incremental cost-effectiveness ratio (ICER) method, were performed from the perspective of CMS's Medicare. Quality-adjusted life years (QALYs) estimated using patient-reported EQ-5D-5L data were used as the effectiveness measure. Health care utilizations were converted to costs using average national Medicare reimbursements. ICERs excluding patients with pre-existing disability, and limited to stroke-related costs were also calculated. RESULTS: The first-year ICER for all tPA-eligible patients using total cost differences between MSU and EMS groups was $238,873/QALY; for patients without pre-existing disability was $61,199/QALY. The lifetime ICERs for all tPA-eligible patients and for those without pre-existing disability were $94,710 and $31,259/QALY, respectively. All ICERs were lower when restricted to stroke-related costs and were highly dependent on the number of patients treated per year in an MSU. INTERPRETATION: MSUs' cost-effectiveness is borderline if we consider total first-year costs and outcomes in all tPA-eligible patients. MSUs are cost-effective to highly cost-effective when calculations are based on patients without pre-existing disability, patients' lifetime horizon, stroke-related costs, and more patients treated per year in an MSU. ANN NEUROL 2025;97:209-221.
引用
- Rajan SS, Yamal JM, Wang M, et al. A Prospective Multicenter Analysis of Mobile Stroke Unit Cost-Effectiveness. Ann Neurol. 2024. PMID: 39625067. doi:10.1002/ana.27105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。